NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 21st March 2012 The ATLAS ACS 2-TIMI 51 trial (n = 15,526) found that rivaroxaban at twice daily doses of 2.5 mg or 5 mg, in addition to standard […]

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 23 February 2012 A randomised, double-blind, 30-week, phase III trial (n = 261) found that adding twice-daily exenatide to basal insulin therapy with insulin glargine improved HbA1c levels in […]

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 21 December 2011 Summary: Data from the two year TEMSO trial have shown that teriflunomide, a once daily oral drug for the treatment of relapsing forms of multiple sclerosis, […]

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 23 November 2011 The ARISTOTLE study found that apixaban▼ 5 mg twice a day reduced the risk of the composite outcome of ischaemic or haemorrhagic stroke or systemic embolism […]

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 18 October 2011 The published data from ROCKET AF in 14,264 patients with nonvalvular atrial fibrillation (AF), who were at moderate to high risk of stroke, found that rivaroxaban […]

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 11 October 2011 The REALIZE trial (n = 663) found that the addition of oral telaprevir▼to standard therapy with peginterferon alfa-ribavirin was significantly more effective than standard treatment alone […]

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 13 September 2011 The ADVANCE trial (n = 1,095) found that in previously untreated patients with genotype 1 hepatitis C infection and a baseline hepatitis C virus RNA level […]

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 2 September 2011 A once-weekly exenatide 2mg suspension for subcutaneous injection (Bydureon ▼®) has recently been launched for the management of type 2 diabetes. This prolonged- release formulation is […]

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 2 August 2011 The HCV RESPOND-2 trial (n=404) found that oral boceprevir given three times a day in addition to peginterferon alfa and ribavirin significantly increased rates of sustained […]

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 14 July 2011 The SPRINT-2 trial (n=1,097) found that oral boceprevir given three times a day, plus standard therapy of peginterferon alfa-ribavirin, significantly increased rates of sustained virologic response […]